scholarly journals Site-specific treatment outcome in smokers following non-surgical and surgical periodontal therapy

2015 ◽  
Vol 42 (10) ◽  
pp. 933-942 ◽  
Author(s):  
Dagmar F. Bunaes ◽  
Stein Atle Lie ◽  
Morten Enersen ◽  
Anne Nordrehaug Aastrøm ◽  
Kamal Mustafa ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Specific Treatment ◽  
Periodontal Therapy ◽  
Site Specific

scholarly journals Site‐specific treatment outcome in smokers following 12 months of supportive periodontal therapy

2016 ◽  
Vol 43 (12) ◽  
pp. 1086-1093 ◽  
Author(s):  
Dagmar F. Bunæs ◽  
Stein Atle Lie ◽  
Anne Nordrehaug Åstrøm ◽  
Kamal Mustafa ◽  
Knut N. Leknes
Keyword(s):  
Treatment Outcome ◽  
Specific Treatment ◽  
Periodontal Therapy ◽  
Site Specific ◽  
Supportive Periodontal Therapy

A multicentre randomized controlled trial on trans-generational attention deficit/hyperactivity disorder (ADHD) in mothers and children (AIMAC): an exploratory analysis of predictors and moderators of treatment outcome

2019 ◽  
Vol 47 (1) ◽  
pp. 49-65 ◽  
Author(s):  
Charlotte Jaite ◽  
Betteke Maria van Noort ◽  
Timo D. Vloet ◽  
Erika Graf ◽  
Viola Kappel ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Primary Outcome ◽  
Controlled Trial ◽  
Specific Treatment ◽  
Externalizing Symptoms ◽  
Control Treatment ◽  
Comorbid Depression ◽  
Adhd Treatment ◽  
Mothers And Children ◽  
Maternal Adhd

Abstract. Objective: We examined predictors and moderators of treatment outcome in mothers and children diagnosed with ADHD in a large multicentre RCT. Method: In total, 144 mother-child dyads with ADHD were randomly assigned to either a maternal ADHD treatment (group psychotherapy and open methylphenidate medication, TG) or to a control treatment (individual counselling without psycho- or pharmacotherapy, CG). After maternal ADHD treatment, parent-child training (PCT) for all mother-child dyads was added. The final analysis set was based on 123 dyads with completed primary outcome assessments (TG: n = 67, CG: n = 56). The primary outcome was the change in each child’s externalizing symptoms. Multiple linear regression analyses were performed. Results: The severity of the child’s externalizing problem behaviour in the family at baseline predicted more externalizing symptoms in the child after PCT, independent of maternal treatment. When mothers had a comorbid depression, TG children showed more externalizing symptoms after PCT than CG children of depressive mothers. No differences between the treatment arms were seen in the mothers without comorbid depression. Conclusions: Severely impaired mothers with ADHD and depressive disorder are likely to need additional disorder-specific treatment for their comorbid psychiatric disorders to effectively transfer the contents of the PCT to the home situation (CCTISRCTN73911400).

Site-specific wild oat (Avena fatua L.) management

2012 ◽  
Vol 92 (5) ◽  
pp. 923-931 ◽  
Author(s):  
H. J. Beckie ◽  
S. Shirriff
Keyword(s):  
Specific Treatment ◽  
Triticum Aestivum L ◽  
Avena Fatua ◽  
Slope Position ◽  
Wild Oat ◽  
Herbicide Application ◽  
Brassica Napus L ◽  
Site Specific ◽  
Lower Slope ◽  
Upper Slope

Beckie, H. J. and Shirriff, S. 2012. Site-specific wild oat ( Avena fatua L.) management. Can. J. Plant Sci. 92: 923–931. Variation in soil properties, such as soil moisture, across a hummocky landscape may influence wild oat emergence and growth. To evaluate wild oat emergence, growth, and management according to landscape position, a study was conducted from 2006 to 2010 in a hummocky field in the semiarid Moist Mixed Grassland ecoregion of Saskatchewan. The hypothesis tested was that wild oat emergence and growth would be greater in lower than upper slope positions under normal or dry early growing season conditions. Three herbicide treatments were imposed on the same plots each year of a 2-yr canola (Brassica napus L.) – wheat (Triticum aestivum L.) sequence: (1) nontreated (weedy) control; (2) herbicide application to upper and lower slope positions (i.e., full or blanket application); and (3) herbicide application to lower slope position only. Slope position affected crop and weed densities before in-crop herbicide application in years with dry spring growing conditions. Site-specific wild oat herbicide application in hummocky fields in semiarid regions may be justified based on results of wild oat control averaged across slope position. In year 2 of the crop sequence (wheat), overall (i.e., lower and upper slope) wild oat control based on density, biomass, and dockage (i.e., seed return) was similar between site-specific and full herbicide treatment in 2 of 3 yr. Because economic thresholds have not been widely adopted by growers in managing wild oat, site-specific treatment in years when conditions warrant may be an appropriate compromise between no application and blanket herbicide application.

scholarly journals Salmonella and cancer: from pathogens to therapeutics.

2013 ◽  
Vol 60 (3) ◽  
Author(s):  
Paulina Chorobik ◽  
Dominik Czaplicki ◽  
Karolina Ossysek ◽  
Joanna Bereta
Keyword(s):  
Clinical Trial ◽  
Cancer Therapy ◽  
Phase I ◽  
Tumor Biology ◽  
Specific Treatment ◽  
Antibody Fragment ◽  
Cancer Therapeutics ◽  
Clinical Development ◽  
Bacterial Strains ◽  
Site Specific

Bacterial cancer therapy is a concept more than 100 years old - yet, all things considered, it is still in early development. While the use of many passive therapeutics is hindered by the complexity of tumor biology, bacteria offer unique features that can overcome these limitations. Microbial metabolism, motility and sensitivity can lead to site-specific treatment, highly focused on the tumor and safe to other tissues. Activation of tumor-specific immunity is another important mechanism of such therapies. Several bacterial strains have been evaluated as cancer therapeutics so far, Salmonella Typhimurium being one of the most promising. S. Typhimurium and its derivatives have been used both as direct tumoricidal agents and as cancer vaccine vectors. VNP20009, an attenuated mutant of S. Typhimurium, shows significant native toxicity against murine tumors and was studied in a first-in-man phase I clinical trial for toxicity and anticancer activity. While proved to be safe in cancer patients, insufficient tumor colonization of VNP20009 was identified as a major limitation for further clinical development. Antibody-fragment-based targeting of cancer cells is one of the few approaches proposed to overcome this drawback.

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients (pts) with carcinoma of unknown primary site (CUP): Results of a prospective Sarah Cannon Research Institute (SCRI) trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10530-10530
Author(s):  
Frank A. Greco ◽  
Mark S. Rubin ◽  
Ralph V. Boccia ◽  
Michael A. Scola ◽  
David R. Spigel ◽  
...  
Keyword(s):  
Prospective Trial ◽  
Specific Treatment ◽  
Molecular Profiling ◽  
Unknown Primary ◽  
Specific Therapy ◽  
Accurate Identification ◽  
Site Specific ◽  
Tissue Of Origin ◽  
Tumor Types ◽  
Tumor Profiling

10530 Background: Tumor profiling is an emergent technique to determine tissue of origin in CUP patients. However, the value of these predictions in improving treatment efficacy is unknown. In this prospective trial, we used tumor profiling results to direct site-specific therapy for CUP pts. Methods: A 92-gene RT-PCR assay (CancerTYPE ID; bioTheranostics, Inc.) was performed on tumor biopsies from previously untreated CUP pts who consented. When a tissue of origin was predicted, pts who were treatment candidates were assigned standard site-specific first-line therapy. Results: Between 10/08 and 12/11, 289 pts were enrolled, 252 had successful assays performed, and 247 (98%) had a tissue of origin predicted. 224 pts were eligible for treatment; 197 pts received assay-directed treatment. 120 of 224 treated pts (54%) had assay diagnoses of tumor types known to derive substantial benefit from standard site-specific treatment (bladder 27, colorectal 26, NSCLC 24, breast 10, ovary 10, kidney 9, prostate 4, germ cell 4, others 6 (3 sites), while 104 pts (46%) had assay diagnoses of relatively resistant tumors (biliary tract 45, pancreas 12, gastroesophageal 10, liver 7, sarcoma 5, cervix 5, others 20 (8 sites). Median OS for all treated pts was 10.8 months (mos); OS for 197 pts with assay-directed treatment was 12.2 mos (versus 6.0 mos for 27 pts receiving empiric therapy). Median OS was better in the 120 pts with assay diagnoses of more responsive tumor types (12.8 vs 7.4 mos; p = .027). Median OS (mos) in specific subgroups: pancreas 9, kidney 12, colon 12, NSCLC 16, ovary 30. Conclusions: This is the first prospective trial in which molecular profiling has directed site-specific therapy in CUP pts. Assay-directed therapy in 197 pts produced a median OS (12.2 mos) that compares favorably with previous empiric CUP therapy. CUP pts predicted to have more responsive tumor types had longer survival compared to less responsive types, suggesting accurate identification by the assay. These results strengthen the rationale for molecular profiling in CUP management.

NGSCUP: Phase II trial of site-specific treatment based on gene expression and mutation profiling by next generation sequencing (NGS) for patients (pts) with cancer of unknown primary site (CUP).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15577-e15577
Author(s):  
Hidetoshi Hayashi ◽  
Yuichi Takiguchi ◽  
Hironobu Minami ◽  
Kohei Akiyoshi ◽  
Yoshihiko Segawa ◽  
...  
Keyword(s):  
Gene Expression ◽  
Survival Rate ◽  
Specific Treatment ◽  
Diagnostic Technique ◽  
Gene Profiling ◽  
Unknown Primary ◽  
Phase 2 ◽  
Site Specific ◽  
One Year ◽  
Tumor Types

e15577 Background: Although gene profiling is a promising diagnostic technique to determine the tissue of origin for pts with CUP, we reported that site-specific treatment based on gene profiling using microarray did not result in an improvement the survival compared with empirical therapy in the previous randomized phase 2 trial (Hayashi, et. al, JCO 2019). Recently, we have established new integrative diagnostic system combined the gene expression from RNA-sequencing and mutation/copy number variation data from targeted genomic-sequencing using NGS. We have performed a single-arm phase 2 study to assess the efficacy of site-specific therapy determined by this system in previously untreated pts with CUP. Methods: Comprehensive gene profiling was performed by NGS, and an established algorithm was applied to predict tumor origin. Pts with CUP was received site-specific chemotherapy determined by the predicted site. The primary endpoint was one-year survival rate. Results: A total of 111 pts was enrolled and all had sufficient biopsy tissue for gene profiling. Efficacy analysis was performed for 97 pts who received site-specific treatment. Cancer types most commonly predicted were lung (21%), liver (15%), kidney (15%), and colorectal cancer (12%). The one-year survival rate, median overall survival (OS), and progression free survival (PFS) was 53.1% (95%CI, 42.6-62.5%), 13.7 months (95% CI, 9.3-19.7 months), and 5.2 months (95% CI, 3.3-7.1 months), respectively. Median OS (15.7 versus 11.0 months, P = .078) and PFS (5.5 versus 2.8 months, P = .019) were better for predicted tumor types categorized as more responsive types than for less responsive ones. Conclusions: Site-specific treatment based on NGS demonstrated promising efficacy. Pts with CUP predicted to have more responsive tumor types had longer survival compared with pts with less responsive tumor types, suggesting that molecular tumor profiling by both DNA and RNA testing contributes to the management of pts with CUP. Clinical trial information: UMIN051180009.

Sign in / Sign up

Export Citation Format

Share Document